Print PDF

Industry Fights Back Against Restrictions on Pharmaceutical Manufacturers’ Ability To Offer Drug Cost-Sharing Subsidies

New York Law Journal

In 2022, the Office of Inspector General and at least two federal courts took a clear stance against pharmaceutical manufacturers’ attempts to offer cost-sharing subsidies to Medicare beneficiaries for certain drugs. However, the industry is fighting back, as partners Scott Liebman and Dominick DiSabatino and associate Audrey Crowell detail in their published in the New York Law Journal.  Pharmaceutical manufacturers and lobbying groups are challenging these administrative restrictions in a concerted effort to increase access to life-saving medications.

Read more here

Practice Areas


Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.